Insiders who reported open-market trades in the last 12 months at the companies David Alan Campbell files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
David Alan Campbell is a corporate insider, tracked as President and CEO, Director of Janux Therapeutics, Inc. (JANX). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has David Alan Campbell submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has David Alan Campbell been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($5.04M) across all tracked filings.
David Alan Campbell is President and CEO, Director of Janux Therapeutics, Inc. (JANX). 6 SEC Form 4 filings on record going back to 2024, most recently on 1 August 2026. Most recent open-market trade: sold $1.40M of JANX on 27 December 2024. Lifetime open-market sales: $5.04M.
Recent transactions
8
The latest 8 SEC Form 4 transactions reported by David Alan Campbell.
InsiderAlpha's records for David Alan Campbell go back to 2024: 6 primary Form 4 filings, an average of 2.0 per year. 6 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
